StockData
Inmune Bio, Inc. logo

Inmune Bio, Inc. (INMB) stock

INMBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$0.96+0.01 (+1.44%)

Close on Nov 17, 2026Market cap $26.64MP/E –Yield –

Inmune Bio operating margin

Operating margin is operating income as a percentage of revenue.

Inmune Bio's operating margin for the twelve months ending Dec 31, 2025 was -94766.0%. For fiscal 2025 it was -94766.0%, against -304535.7% the year before. The highest annual figure on record is -6938.8% in fiscal 2022.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-94766.0%+209769.7
FY2024Dec 31, 2024-304535.7%−285348.0
FY2023Dec 31, 2023-19187.7%−12249.0
FY2022Dec 31, 2022-6938.8%+9167.9
FY2021Dec 31, 2021-16106.6%+95057.0
FY2020Dec 31, 2020-111163.6%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q1 FY2025Mar 31, 2025-19810.0%−5873.0
Q1 FY2024Mar 31, 2024-78692.9%−61790.2
Q4 FY2023Dec 31, 2023-29925.0%−24108.5
Q3 FY2023Sep 30, 2023-19832.6%−12237.7
Q2 FY2023Jun 30, 2023-13937.0%+25988.0
Q1 FY2023Mar 31, 2023-16902.6%−12928.4
Q4 FY2022Dec 31, 2022-5816.5%−276.6
Q3 FY2022Sep 30, 2022-7594.9%+56840.8
Q2 FY2022Jun 30, 2022-39925.0%+73775.0
Q1 FY2022Mar 31, 2022-3974.2%–
Q4 FY2021Dec 31, 2021-5539.9%–
Q3 FY2021Sep 30, 2021-64435.7%–
Q1 FY2021Mar 31, 2021-113700.0%–

More Inmune Bio figures

See a number that looks wrong?